Abbott Laboratories (NYSE:ABT): A High-Quality Dividend Stock with Strong Growth and Financial Health

Dividend investing focuses on identifying companies that not only provide consistent income through payouts but also demonstrate the financial strength to sustain and grow those dividends over time. The "Best Dividend Stocks" screen filters for securities with a high ChartMill Dividend Rating (≥7), ensuring strong dividend characteristics, while also requiring a minimum ChartMill Profitability Rating (≥5) and Health Rating (≥5) to confirm the company's earnings stability and balance sheet resilience. This approach helps investors avoid high-yield traps, companies with unsustainable payouts, while prioritizing quality and sustainability.

Abbott Laboratories (NYSE:ABT) stands out as a strong candidate from this screen, reflecting solid dividend metrics alongside good profitability and financial health.

Dividend Strength: Reliability and Growth

ABT’s Dividend Rating of 7/10 is supported by several key factors:

• Track Record: The company has increased its dividend for at least 10 consecutive years, signaling management’s commitment to returning capital to shareholders.
• Dividend Growth: ABT’s annualized dividend growth rate of 11.4% over the past five years outpaces many peers, reflecting its ability to compound income for investors.
• Sustainable Payout Ratio: At 28.9% of earnings, the dividend is well-covered, leaving ample room for reinvestment and future hikes. While earnings growth has lagged dividend growth recently (a noted risk), ABT’s strong profitability metrics (discussed below) provide a buffer.
• Competitive Yield: ABT’s 1.88% yield is modest but exceeds the industry average (1.78%) and aligns with its sector’s conservative payout norms. For context, the S&P 500 average yield is 2.32%.

These traits align with the screen’s goal of identifying dividends that are not just high but also durable. As highlighted in our dividend evaluation guide, sustainability and growth potential are critical to long-term income investing.

Profitability: Earnings Power Supports Payouts

ABT’s Profitability Rating of 8/10 highlights its capacity to generate cash:

• High Margins: A 31.9% net profit margin ranks in the top 3% of its healthcare equipment peers, while its 17.4% operating margin reflects efficient cost management. Both metrics have improved in recent years.
• Strong Returns: ABT’s 27.7% return on equity (ROE) and 16.6% return on assets (ROA) outperform 97% of industry competitors, demonstrating effective capital allocation.

These metrics are vital for dividend investors, as consistent profitability ensures dividends aren’t funded by debt or asset sales.

Financial Health: A Resilient Balance Sheet

With a Health Rating of 7/10, ABT maintains a low-risk financial profile:

• Solvency: A Debt/Equity ratio of 0.26 and Altman-Z score of 5.84 (indicating low bankruptcy risk) reflect conservative leverage. The company could repay all debt in 1.99 years using its free cash flow.
• Liquidity Caveat: ABT’s current ratio (1.78) and quick ratio (1.27) trail 70% of peers, but this is offset by strong cash flow and profitability. As noted in the fundamental report, such ratios are less concerning for stable businesses like ABT.

Valuation and Growth Considerations

ABT trades at a 25.8x P/E ratio, slightly below its industry (29.1x) and the S&P 500 (28.0x). While not cheap, this premium reflects its reliable growth:

• Revenue and EPS Growth: Past 5-year EPS growth (7.6%) and revenue growth (5.6%) are steady, with analysts projecting acceleration to 9.8% EPS growth and 7.2% revenue growth annually.

For dividend investors, ABT offers a balance of yield, growth, and safety. Its modest yield may not appeal to high-income seekers, but its dividend growth trajectory and financial resilience make it a candidate for compounding returns.

Explore More Dividend Ideas

The Best Dividend Stocks screen surfaces additional companies meeting these criteria. Adjust filters like yield or market cap to refine results further.

Disclaimer: This analysis is not investment advice. Conduct your own research or consult a financial advisor before making decisions.